Kevin Eisele, managing director in William Blair’s Equity Capital Markets group, was quoted in biopharma industry publication Endpoints News on the current state of PIPE structures for investing in companies in the sector.
“At the end of the day, the investment is made on a fundamental basis about the company, or the strength of its data or some strategic aspect that makes it compelling,” Eisele told the publication.